Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | FLT4 | P35916 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30628195 | 1.00 | FLT1 (0.51) | FLT1FLT4KDRCYP11B2NPC1 | |
| SCHEMBL250256 | 0.84 | FLT1 (0.53) | FLT1FLT4KDRCYP11B2NPC1 | |
| SCHEMBL107882 | 0.83 | FLT1 (0.51) | FLT1FLT4KDRCYP11B2NPC1 | |
| SCHEMBL109654 | 0.83 | SMN1; SMN2 (0.63) | FLT1FLT4KDRNPC1RAB9A | |
| SCHEMBL3922668 | 0.83 | ALDH1A1 (0.47) | NPC1RAB9ASMN1; SMN2TSHRCASP1 | |
| SCHEMBL20117002 | 0.82 | ALDH1A1 (0.50) | SMN1; SMN2TSHRCASP1MAPTMAOB | |
| SCHEMBL11255876 | 0.81 | FLT1 (0.50) | FLT1FLT4KDRCYP11B2NPC1 | |
| Hydrochloric Acid SCHEMBL14660084 | 0.81 | SMN1; SMN2 (0.61) | FLT1FLT4KDRNPC1RAB9A | |
| SCHEMBL9555496 | 0.81 | FLT1 (0.50) | FLT1FLT4KDRCYP11B2NPC1 | |
| SCHEMBL2468739 | 0.81 | KDM4E (0.55) | FLT1FLT4KDRCYP11B2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2021057818-A1 | FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3166937-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-08-09 | — | — | US | disclosed |
| US-9968596-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2018-05-15 | — | — | US | disclosed |
| US-20180093969-A1 | Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | VERTEX PHARMACEUTICALS INCORPORATED | 2018-04-05 | — | — | US | disclosed |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-01-25 | — | — | US | disclosed |
| WO-1989007593-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1989-08-24 | — | — | WO | disclosed |
| US-4517318-A | BENZOPHENONE AND TRANSITION METALCOMPOUNT ACCELERATOR | Sekisu Kagaku Kogyo Kabushiki Kaisha (JP) | 1985-05-14 | — | — | US | disclosed |
| US-4495315-A | BENZOPHENONE-TYPE COMPOUNDS AS DEGRADING AGENT- TRANSITION METAL ACCELERATORS | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-01-22 | — | — | US | disclosed |
| EP-0093488-A2 | Nortropyl benzopyrrolinone compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-11-09 | — | — | EP | disclosed |
| US-4393062-A | ALDOSE REDUCTASE INHIBITOR | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-07-12 | — | — | US | disclosed |
| US-4337341-A | 4a-Aryl-octahydro-1H-2-pyrindines | ELI LILLY AND COMPANY (US) | 1982-06-29 | — | — | US | disclosed |
| EP-0002895-B1 | ENZYME INHIBITORY PHTHALAZIN-4-YLACETIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND PROCESS FOR THEIR MANUFACTURE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-10-14 | — | — | EP | disclosed |
| US-4251528-A | ALDOSE REDUCTASE INHIBITORS USEFUL IN DIABETES, GALACTOSEMIA | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-02-17 | — | — | US | disclosed |
| EP-0002895-A1 | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-07-11 | — | — | EP | disclosed |
| EP-0002937-A1 | Novel pyrindines and their preparation, formulations and use | ELI LILLY AND COMPANY (US) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | FLT1 3302/4885FLT4 3962/4885KDR 3702/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | FLT1 3302/4885FLT4 3962/4885KDR 3702/4885 |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | FLT1 3302/4885FLT4 3962/4885KDR 3702/4885 |
| US-20180093969-A1 | Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | CFTR, SLC26A4, ABCB11 | FLT1 4475/4885FLT4 4569/4885KDR 4444/4885 |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | FLT1 3302/4885FLT4 3962/4885KDR 3702/4885 |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | FLT1 3302/4885FLT4 3962/4885KDR 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.